Fig. 2: NAT10 promotes pancreatic cancer proliferation and metastasis. | Cell Death & Disease

Fig. 2: NAT10 promotes pancreatic cancer proliferation and metastasis.

From: Targeting the ac4C ‘Writer’ NAT10 enhances pancreatic cancer immunotherapy via dual modulation of CD8+ T cells and tumor cells

Fig. 2: NAT10 promotes pancreatic cancer proliferation and metastasis.

A Knockdown efficiency of NAT10 mRNA in PANC-1 and AsPC-1 cells. NAT10 mRNA levels were significantly lower in the sh-NAT10#1 and sh-NAT10#2 groups than in the sh-NC group (P < 0.001).B Efficiency of NAT10 mRNA overexpression in CFPAC-1 and MIA PaCa-2 cells. NAT10 mRNA levels were significantly increased in lv-NAT10 cells compared with lv-NC controls (P < 0.001). C, D Western blot analysis confirmed significant knockdown of NAT10 protein in PANC-1 and AsPC-1 cells. E, F Western blot analysis revealed significantly elevated NAT10 protein levels in lv-NAT10 CFPAC-1 and MIA PaCa-2 cells compared with lv-NC controls. G, H NAT10 knockdown significantly inhibited the viability of PANC-1 and AsPC-1 cells over 5 days (P < 0.001). I, J NAT10 overexpression significantly promoted the viability of CFPAC-1 and MIA PaCa-2 cells over 5 days (P < 0.001). K–N Colony formation assays revealed that NAT10 knockdown reduced colony numbers in PANC-1 and AsPC-1 cells (P < 0.001), whereas NAT10 overexpression increased colony numbers in CFPAC-1 and MIA PaCa-2 cells (P < 0.001). O–R Transwell assays revealed that NAT10 knockdown significantly reduced the migration of PANC-1 and AsPC-1 cells (P < 0.001), whereas NAT10 overexpression enhanced the migratory ability of CFPAC-1 and MIA PaCa-2 cells (P < 0.001).

Back to article page